Corporate Presentation

Exicure is Advancing a Deep Pipeline NEUROLOGY XCUR-FXN CLN3 SCN9A Discovery Programs IMMUNO-ONCOLOGY DERMATOLOGY CAVROTOLIMOD (TLR9 AGONIST) XCUR17 (ANTI-IL17RA) Undisclosed Target Undisclosed Target 1) In combination with checkpoint inhibitors ACA FRIEDREICH'S ATAXIA BATTEN DISEASE NEUROPATHIC PAIN ALS, SCAS, ANGELMAN'S MERKEL CELL CARCINOMA¹ CUTANEOUS SQUAMOUS CELL CARCINOMA¹ INFLAMMATORY DISORDERS HAIR LOSS DISORDERS NETHERTON SYNDROME DISCOVERY PRECLINICAL DEV IND-enabling PHASE 1 abbvie DERMELIX BIOTHERAPEUTICS PHASE 2 exicure | 10

View entire presentation